New Document
Corporate Profile Products Investor Relations News Room Careers Contact Us Manufacturing Quality Assurance Environment, Health & Safety R & D Contract Research & Manufacturing Home
 

Financial Year 2007 - 2008

Quarter IV
(March 2008)

Quarter III
(December 2007)

Quarter II
(September 2007)

Quarter I
(June 2007)

Financial Year 2006 - 2007

Quarter IV
(March 2007)

Quarter III
(December 2006)

Quarter II
(September 2006)

Quarter I
(June 2006)
Financial Year 2005 - 2006

Quarter III
(December 2005)

Quarter II
(September 2005)

Quarter I
(June 2005)

Financial Year 2004 - 2005

Quarter IV
(March 2005)

Quarter III
(December 2004)

Quarter II
(September 2004)

Quarter I
(June 2004)

Financial Year 2003 - 2004

Quarter IV
(March 2004)

Quarter III
(December 2003)

Quarter II
(September 2003)

Quarter I
(June 2003)

Financial Year 2002 - 2003

Quarter IV
(March 2003)

Quarter III
(December 2002)

Quarter II
(September 2002)

Quarter I
(June 2002)


MATRIX LABORATORIES LIMITED
1-1-151/1, IV FLOOR, SAIRAM TOWERS, ALEXANDER ROAD SECUNDERABAD- 500 003
UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2004

(Rs.in Million )
Sl. No Particulars "Quarter ended
30th June"
"Year ended 31st March 2004
(Unaudited)"
"Year Ended 31st March 2003
(Audited)"
2004
(Unaudited)
2003
(Audited)
  Gross Sales
- Exports
- Domestic
1631.52
913.80
717.72
1270.27
768.06
502.21
5604.27
3104.02
2500.25
4169.27
2888.47
1280.80
01.
02.
03.




04.
05.
06.
07.
08.
09.
10.

11.

12.

13.

14.

15.



16.



17.
Net Sales
Other Income
Total Expenditure
a) (Increase) / Decrease in Stock
b) Consumption of Raw materials
c) Staff Cost
d) Other Expenditure
Interest
Depreciation
Profit before Tax (1+2-3-4-5)
Provision for Tax - Current
                             - Deferred
Profit after Tax (6-7-8)
Prior period adjustments including taxes
Profit after Tax and
adjustments (9-10)
Equity Capital (fully paid
up Rs. 10 each)
Share Capital suspense

Reserves excluding revaluation reserves
Basic E.P.S in Rs.
- Not Annualised (Rs.)
-Annualised (Rs.)

Diluted E.P.S in Rs.
- Not Annualised (Rs.)
-Annualised (Rs.)

Aggregate of Non promoters Shareholding
Number of shares
Percentage of Shareholding
1539.97
25.60
1069.18
90.04
610.79
65.54
302.81
11.91
37.07
447.41
30.00
10.00
407.41
-

407.41

145.54

-


-

30.83
123.32


29.89
119.56



9135134
62.79%
1201.15
9.33
821.30
(30.05)
579.31
44.97
217.17
20.49
21.50
357.09
25.00
25.00
307.09
-

307.09

97.18

25.79


-

24.95
99.80


24.95
99.80



4403984
45.32%
5327.21
62.31
3544.21
(407.95)
2695.26
201.68
1055.22
152.65
110.45
1582.21
148.00
85.00
1349.21
2.91

1346.30

123.03

-




-
109.47


-
107.84



6797134
55.27%
3955.25
7.72
2674.93
21.61
1672.08
142.24
839.00
260.39
71.96
955.69
57.00
147.24
751.45
0.91

750.54

97.18

25.79


892.62

-
98.78


-
73.74



4430164
45.59%
Notes :
1.

The above unaudited results were reviewed by the Audit Committee, considered and approved by the Board of Directors at their meeting held on 17th July 2004.

2.

Other Expenditure includes foreign exchange fluctuation of Rs.72.22 Million on account of reinstatement of foreign currency loans and other monetary items.

3.

Pending approval for the Scheme of Amalgamation by the members of the company and the Hon'ble High Court of Andhra Pradesh for the merger of Vera Laboratories Limited , Fine Drugs and Chemicals Limited , Medikon Laboratories Limited and Calibre Engineering Pvt. Limited into Matrix Laboratories Limited from 1st January 2004, the financial results of the said companies are not included above. Diluted EPS, however has been computed taking into account the equity shares to be issued to the shareholders of Amalgamating Companies as per the said Scheme.

4.

The activities of the Company relate to only one segment i.e. Pharmaceuticals.

5.

Paid-up Share capital increased by Rs.22.50 Millions and Security Premium by Rs.3352.50 Millions consequent to issue of 22,50,000 equity shares of Rs.10/- each at a price of Rs.1500/- per share on preferential basis to India Newbridge Investments Ltd. (an investment vehicle of Newbridge Capital LLC ) and Maxwell (Mauritius) Pte Ltd (an investment vehicle of Temasek Holdings (Private) Limited)

6.

Summary of Investor Complaints :

Opening : Nil , Received during the quarter : 1 , Resolved : 1 ,Closing : Nil

  For and on behalf of the Board



Place : Secunderabad
Date : 17th July 2004
N.PRASAD
Chairman and Chief Executive Officer


Foote Page